药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Methylphenobarbital
Rabies virus inactivated antigen, A
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Docetaxel.
Methylphenobarbital
Rotavirus vaccine
The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Docetaxel.
Methylphenobarbital
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Docetaxel.
Methylphenobarbital
Rabies virus inactivated antigen, B
The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Docetaxel.
Methylphenobarbital
Anthrax immune globulin human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Docetaxel.
Methylphenobarbital
TG4010
The therapeutic efficacy of TG4010 can be decreased when used in combination with Docetaxel.
Methylphenobarbital
Vitespen
The therapeutic efficacy of Vitespen can be decreased when used in combination with Docetaxel.
Methylphenobarbital
GI-5005
The therapeutic efficacy of GI-5005 can be decreased when used in combination with Docetaxel.
Methylphenobarbital
SRP 299
The therapeutic efficacy of SRP 299 can be decreased when used in combination with Docetaxel.
Methylphenobarbital
Rindopepimut
The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Docetaxel.
Methylphenobarbital
INGN 225
The therapeutic efficacy of INGN 225 can be decreased when used in combination with Docetaxel.
Methylphenobarbital
PEV3A
The therapeutic efficacy of PEV3A can be decreased when used in combination with Docetaxel.
Methylphenobarbital
G17DT
The therapeutic efficacy of G17DT can be decreased when used in combination with Docetaxel.
Methylphenobarbital
Pertuzumab
The risk or severity of cardiotoxicity can be increased when Docetaxel is combined with Pertuzumab.
Methylphenobarbital
Paclitaxel poliglumex
The risk or severity of cardiotoxicity can be increased when Docetaxel is combined with Paclitaxel poliglumex.
Methylphenobarbital
Paclitaxel trevatide
The risk or severity of cardiotoxicity can be increased when Docetaxel is combined with Paclitaxel trevatide.
Methylphenobarbital
Aldoxorubicin
The risk or severity of cardiotoxicity can be increased when Docetaxel is combined with Aldoxorubicin.
Methylphenobarbital
Nedaplatin
The risk or severity of adverse effects can be increased when Nedaplatin is combined with Docetaxel.
Methylphenobarbital
Platinum
The risk or severity of adverse effects can be increased when Platinum is combined with Docetaxel.
Methylphenobarbital
Satraplatin
The risk or severity of adverse effects can be increased when Satraplatin is combined with Docetaxel.